Literature DB >> 36227507

Friend and foe: the regulation network of ascites components in ovarian cancer progression.

Zhe Geng1, Xinxing Pan1, Juan Xu2, Xuemei Jia3.   

Abstract

The tumor microenvironment (TME) and its complex role in cancer progression have been hotspots of cancer research in recent years. Ascites, which occurs frequently in patients with ovarian cancer especially in advanced stages, represents a unique TME. Malignant ascites contains abundant cellular and acellular components that play important roles in tumorigenesis, growth, metastasis, and chemoresistance of ovarian cancer through complex molecular mechanisms and signaling pathways. As a valuable liquid biopsy sample, ascites fluid is also of great significance for the prognostic analysis of ovarian cancer. The components of ovarian cancer ascites are generally considered to comprise tumor-promoting factors; however, in recent years studies have found that ascites also contains tumor-suppressing factors, raising new perspectives on interactions between ascites and tumors. Malignant ascites directly constitutes the ovarian cancer microenvironment, therefore, the study of its components will aid in the development of new therapeutic strategies. This article reviews the current research on tumor-promoting and tumor-suppressing factors and molecular mechanisms of their actions in ovarian cancer-derived ascites and therapeutic strategies targeting ascites, which may provide references for the development of novel therapeutic targets for ovarian cancer in the future.
© 2022. The International CCN Society.

Entities:  

Keywords:  Ascites; Ovarian cancer; Therapeutic strategy; Tumor microenvironment; Tumor-promoting and tumor-suppressing factors

Year:  2022        PMID: 36227507     DOI: 10.1007/s12079-022-00698-8

Source DB:  PubMed          Journal:  J Cell Commun Signal        ISSN: 1873-9601            Impact factor:   5.908


  140 in total

Review 1.  Malignant ascites: past, present, and future.

Authors:  Rony A Adam; Yehuda G Adam
Journal:  J Am Coll Surg       Date:  2004-06       Impact factor: 6.113

2.  Correction of aberrant growth preserves tissue homeostasis.

Authors:  Samara Brown; Cristiana M Pineda; Tianchi Xin; Jonathan Boucher; Kathleen C Suozzi; Sangbum Park; Catherine Matte-Martone; David G Gonzalez; Julie Rytlewski; Slobodan Beronja; Valentina Greco
Journal:  Nature       Date:  2017-08-02       Impact factor: 49.962

3.  Fibroblast Subtypes Regulate Responsiveness of Luminal Breast Cancer to Estrogen.

Authors:  Heather M Brechbuhl; Jessica Finlay-Schultz; Tomomi M Yamamoto; Austin E Gillen; Diana M Cittelly; Aik-Choon Tan; Sharon B Sams; Manoj M Pillai; Anthony D Elias; William A Robinson; Carol A Sartorius; Peter Kabos
Journal:  Clin Cancer Res       Date:  2016-10-04       Impact factor: 12.531

Review 4.  Tumour microenvironment and metabolic plasticity in cancer and cancer stem cells: Perspectives on metabolic and immune regulatory signatures in chemoresistant ovarian cancer stem cells.

Authors:  Nuzhat Ahmed; Ruth Escalona; Dilys Leung; Emily Chan; George Kannourakis
Journal:  Semin Cancer Biol       Date:  2018-10-11       Impact factor: 15.707

5.  Effect of purified glutaminase from human ascites fluid on experimental tumor bearing mice.

Authors:  P Bhattacharya; S Sett; P Maity
Journal:  J Exp Clin Cancer Res       Date:  2001-12

6.  Metabolic Alterations and WNT Signaling Impact Immune Response in HGSOC.

Authors:  Rebecca C Arend; Carly B Scalise; Emily R Gordon; Allison M Davis; McKenzie E Foxall; Bobbi E Johnston; David K Crossman; Sara J Cooper
Journal:  Clin Cancer Res       Date:  2022-04-01       Impact factor: 13.801

7.  Correlation of NK T-like CD3+CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF and TNFalpha in ascites from advanced ovarian cancer: Association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapy.

Authors:  Aristotelis Bamias; Vasiliki Koutsoukou; Evangelos Terpos; Marinos L Tsiatas; Christina Liakos; Ourania Tsitsilonis; Alexandros Rodolakis; Zannis Voulgaris; G Vlahos; Theocharis Papageorgiou; G Papatheodoridis; A Archimandritis; A Antsaklis; M A Dimopoulos
Journal:  Gynecol Oncol       Date:  2007-11-26       Impact factor: 5.482

8.  Does VEGF facilitate local tumor growth and spread into the abdominal cavity by suppressing endothelial cell adhesion, thus increasing vascular peritoneal permeability followed by ascites production in ovarian cancer?

Authors:  Inga Bekes; Thomas W P Friedl; Tanja Köhler; Volker Möbus; Wolfgang Janni; Achim Wöckel; Christine Wulff
Journal:  Mol Cancer       Date:  2016-02-12       Impact factor: 27.401

9.  Interleukin-10 and prostaglandin E2 have complementary but distinct suppressive effects on Toll-like receptor-mediated dendritic cell activation in ovarian carcinoma.

Authors:  Eva Brencicova; Ann L Jagger; Hayley G Evans; Mirella Georgouli; Alex Laios; Steve Attard Montalto; Gautam Mehra; Jo Spencer; Ahmed A Ahmed; Shanti Raju-Kankipati; Leonie S Taams; Sandra S Diebold
Journal:  PLoS One       Date:  2017-04-14       Impact factor: 3.240

10.  Myeloid Derived Suppressor Cells: Key Drivers of Immunosuppression in Ovarian Cancer.

Authors:  Thaïs Baert; Ann Vankerckhoven; Matteo Riva; Anaïs Van Hoylandt; Gitte Thirion; Gerhardt Holger; Thomas Mathivet; Ignace Vergote; An Coosemans
Journal:  Front Immunol       Date:  2019-06-04       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.